Q-omics provides the consensus-scored SASS6 profile across patient tissues and cancer cell-line models. SASS6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SASS6 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, SASS6 RNA expression shows 22,332 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where SASS6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SASS6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SASS6 survival associations across molecular data types. SASS6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SASS6 RNA expression–survival associations across cancer types. High SASS6 expression shows unfavorable associations in KIRP, ACC, LIHC, KICH, MESO and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SASS6 RNA expression.
This table summarizes SASS6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SASS6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SASS6 shows higher tumor expression in HNSC, LUAD, BLCA, STAD, LIHC and LUSC. The HNSC box plot shows higher SASS6 RNA expression in tumor versus normal tissue (log2 FC = +1.110, t-test p < 0.001).
This table shows molecular features associated with SASS6 in patient tissues and cancer cell lines. In patient samples, SASS6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SASS6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
